Allergy, Asthma and Clinical Research Center | Oklahoma City, OK

Research site

(Unclaimed)

Location

4200 W Memorial Road, Suite 206, Oklahoma City, Oklahoma, United States of America

Site insights

Top conditions

Top treatments

Dupilumab

azelastine hydrochloride

Omalizumab

Mometasone furoate

azelastineHcl

Aerovant

Amlitelimab

fluticasone propionate

OM-85

DUPIXENT®

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 26 total trials

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (CEREN-2)

EFC18419 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the...

Enrolling

Chronic Rhinosinusitis With Nasal Polyps

Drug: Mometasone furoate nasal spray (MFNS)

Drug: Itepekimab (SAR440340)

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheez...

Active, not recruiting

Wheezing Lower Respiratory Illness

Recurrent Wheezing

Drug: OM-85

Drug: Placebo

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have (ENGAGE)

This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with o...

Active, not recruiting

Eosinophilic Duodenitis (EoD)

Eosinophilic Gastroenteritis

Drug: Dupilumab

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

This is an open-label, multicenter, phase 4 study in IG treatment-naïve participants with PID, conducted in the United States (US), to assess the PK,...

Enrolling

Primary Immunodeficiency

Biological: IgPro

Locations recently updated

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps (Re-Open 3)

This is a 12-Week randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of intranasal ad...

Enrolling

Chronic Rhinosinusitis Without Nasal Polyps

Drug: OPN-375

Drug: Placebo

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (AIM4:Next Step)

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the air...

Enrolling

Asthma

Drug: dupilumab

Drug: Matching Placebo